Diabetes, Vol 49, Issue 4 539-547, Copyright © 2000 by American Diabetes Association

ARTICLES

Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone

HS Camp, O Li, SC Wise, YH Hong, CL Frankowski, X Shen, R Vanbogelen and T Leff
Department of Cell Biology, Warner-Lambert Company, Ann Arbor, Michigan, USA.

The antidiabetic thiazolidinediones, which include troglitazone and rosiglitazone, are ligands for the nuclear receptor peroxisome proliferator-activated receptor (PPAR)-gamma and exert their antihyperglycemic effects by regulation of PPAR-gamma-responsive genes. We report here that PPAR-gamma activation by troglitazone depends on the experimental setting. Troglitazone acts as a partial agonist for PPAR-gamma in transfected muscle (C2C12) and kidney (HEK 293T) cells, producing a submaximal transcriptional response (1.8- to 2.5-fold activation) compared with rosiglitazone (7.4- to 13-fold activation). Additionally, troglitazone antagonizes rosiglitazone-stimulated PPAR-gamma transcriptional activity. Limited protease digestion of PPAR-gamma suggests conformational differences in the receptor bound to troglitazone versus rosiglitazone. Consistent with this finding, an in vitro coactivator association assay demonstrated that troglitazone-bound PPAR-gamma recruited the transcriptional coactivators p300 and steroid receptor coactivator 1 less efficiently than rosiglitazone-bound receptor. In contrast to these observations, troglitazone behaves as a full agonist of PPAR-gamma in 3T3L1 adipocytes. Two-dimensional protein gel electrophoresis demonstrated that troglitazone and rosiglitazone regulated distinct but overlapping sets of genes in several cell types. Thus, troglitazone may behave as a partial agonist under certain physiological circumstances and as a full agonist in others. These differences could be caused by variations in the amount of specific cofactors, differences in PPAR response elements, or the presence of different isoforms of PPAR-gamma.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				F. Turturro, R. Oliver III, E. Friday, I. Nissim, and T. Welbourne Troglitazone and pioglitazone interactions via PPAR-{gamma}-independent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines Am J Physiol Cell Physiol, March 1, 2007; 292(3): C1137 - C1146. [Abstract] [Full Text] [PDF]

				M. Wirtenberger, S. Tchatchou, K. Hemminki, J. Schmutzhard, C. Sutter, R. K. Schmutzler, A. Meindl, B. Wappenschmidt, M. Kiechle, N. Arnold, et al. Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer Carcinogenesis, November 1, 2006; 27(11): 2201 - 2208. [Abstract] [Full Text] [PDF]

				X. Yu, P. A. Egner, J. Wakabayashi, N. Wakabayashi, M. Yamamoto, and T. W. Kensler Nrf2-mediated Induction of Cytoprotective Enzymes by 15-Deoxy-{Delta}12,14-Prostaglandin J2 Is Attenuated by Alkenal/one Oxidoreductase J. Biol. Chem., September 8, 2006; 281(36): 26245 - 26252. [Abstract] [Full Text] [PDF]

				J. P. Vanden Heuvel, J. T. Thompson, S. R. Frame, and P. J. Gillies Differential Activation of Nuclear Receptors by Perfluorinated Fatty Acid Analogs and Natural Fatty Acids: A Comparison of Human, Mouse, and Rat Peroxisome Proliferator-Activated Receptor-{alpha}, -{beta}, and -{gamma}, Liver X Receptor-{beta}, and Retinoid X Receptor-{alpha} Toxicol. Sci., August 1, 2006; 92(2): 476 - 489. [Abstract] [Full Text] [PDF]

				F. F. Samaha, P. O. Szapary, N. Iqbal, M. M. Williams, L. T. Bloedon, A. Kochar, M. L. Wolfe, and D. J. Rader Effects of Rosiglitazone on Lipids, Adipokines, and Inflammatory Markers in Nondiabetic Patients With Low High-Density Lipoprotein Cholesterol and Metabolic Syndrome Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 624 - 630. [Abstract] [Full Text] [PDF]

				N. A. Cataldo, F. Abbasi, T. L. McLaughlin, M. Basina, P. Y. Fechner, L. C. Giudice, and G. M. Reaven Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome Hum. Reprod., January 1, 2006; 21(1): 109 - 120. [Abstract] [Full Text] [PDF]

				A. Lemay, S. Dodin, L. Turcot, F. Dechene, and J-C. Forest Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance Hum. Reprod., January 1, 2006; 21(1): 121 - 128. [Abstract] [Full Text] [PDF]

				M. Schupp, M. Clemenz, R. Gineste, H. Witt, J. Janke, S. Helleboid, N. Hennuyer, P. Ruiz, T. Unger, B. Staels, et al. Molecular Characterization of New Selective Peroxisome Proliferator-Activated Receptor {gamma} Modulators With Angiotensin Receptor Blocking Activity Diabetes, December 1, 2005; 54(12): 3442 - 3452. [Abstract] [Full Text] [PDF]

				T. J. Standiford, V. G. Keshamouni, and R. C. Reddy Peroxisome Proliferator-activated Receptor-{gamma} as a Regulator of Lung Inflammation and Repair Proceedings of the ATS, October 1, 2005; 2(3): 226 - 231. [Abstract] [Full Text] [PDF]

				J. A. Polikandriotis, L. J. Mazzella, H. L. Rupnow, and C. M. Hart Peroxisome Proliferator-Activated Receptor {gamma} Ligands Stimulate Endothelial Nitric Oxide Production Through Distinct Peroxisome Proliferator-Activated Receptor {gamma}-Dependent Mechanisms Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1810 - 1816. [Abstract] [Full Text] [PDF]

				R. Oliver III, E. Friday, F. Turturro, A. Lacy, and T. Welbourne Troglitazone's rapid and sustained activation of ERK1/2 induces cellular acidosis in LLC-PK1-F+ cells: physiological responses Am J Physiol Renal Physiol, June 1, 2005; 288(6): F1257 - F1266. [Abstract] [Full Text] [PDF]

				Y. Yin, R. G. Russell, L. E. Dettin, R. Bai, Z.-L. Wei, A. P. Kozikowski, L. Kopleovich, and R. I. Glazer Peroxisome Proliferator-Activated Receptor {delta} and {gamma} Agonists Differentially Alter Tumor Differentiation and Progression during Mammary Carcinogenesis Cancer Res., May 1, 2005; 65(9): 3950 - 3957. [Abstract] [Full Text] [PDF]

				J. Hwang, D. J. Kleinhenz, B. Lassegue, K. K. Griendling, S. Dikalov, and C. M. Hart Peroxisome proliferator-activated receptor-{gamma} ligands regulate endothelial membrane superoxide production Am J Physiol Cell Physiol, April 1, 2005; 288(4): C899 - C905. [Abstract] [Full Text] [PDF]

				H. Duez, B. Lefebvre, P. Poulain, I. P. Torra, F. Percevault, G. Luc, J. M. Peters, F. J. Gonzalez, R. Gineste, S. Helleboid, et al. Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator-Activated Receptor {alpha} Modulation Arterioscler. Thromb. Vasc. Biol., March 1, 2005; 25(3): 585 - 591. [Abstract] [Full Text] [PDF]

				Y. Xu, M. Gen, L. Lu, J. Fox, S. O. Weiss, R. D. Brown, D. Perlov, H. Ahmad, P. Zhu, C. Greyson, et al. PPAR-{gamma} activation fails to provide myocardial protection in ischemia and reperfusion in pigs Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1314 - H1323. [Abstract] [Full Text] [PDF]

				Y. Rival, A. Stennevin, L. Puech, A. Rouquette, C. Cathala, F. Lestienne, E. Dupont-Passelaigue, J.-F. Patoiseau, T. Wurch, and D. Junquero Human Adipocyte Fatty Acid-Binding Protein (aP2) Gene Promoter-Driven Reporter Assay Discriminates Nonlipogenic Peroxisome Proliferator-Activated Receptor {gamma} Ligands J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 467 - 475. [Abstract] [Full Text] [PDF]

				F. Turturro, E. Friday, R. Fowler, D. Surie, and T. Welbourne Troglitazone Acts on Cellular pH and DNA Synthesis through a Peroxisome Proliferator-Activated Receptor {gamma}-Independent Mechanism in Breast Cancer-Derived Cell Lines Clin. Cancer Res., October 15, 2004; 10(20): 7022 - 7030. [Abstract] [Full Text] [PDF]

				M A. Soroceanu, D. Miao, X.-Y. Bai, H. Su, D. Goltzman, and A. C Karaplis Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis J. Endocrinol., October 1, 2004; 183(1): 203 - 216. [Abstract] [Full Text] [PDF]

				Y. Tanabe, M. Koga, M. Saito, Y. Matsunaga, and K. Nakayama Inhibition of adipocyte differentiation by mechanical stretching through ERK-mediated downregulation of PPAR{gamma}2 J. Cell Sci., July 15, 2004; 117(16): 3605 - 3614. [Abstract] [Full Text] [PDF]

				S. C. Benson, H. A. Pershadsingh, C. I. Ho, A. Chittiboyina, P. Desai, M. Pravenec, N. Qi, J. Wang, M. A. Avery, and T. W. Kurtz Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPAR{gamma}-Modulating Activity Hypertension, May 1, 2004; 43(5): 993 - 1002. [Abstract] [Full Text] [PDF]

				C. L. Varley, J. Stahlschmidt, W.-C. Lee, J. Holder, C. Diggle, P. J. Selby, L. K. Trejdosiewicz, and J. Southgate Role of PPAR {gamma} and EGFR signalling in the urothelial terminal differentiation programme J. Cell Sci., April 15, 2004; 117(10): 2029 - 2036. [Abstract] [Full Text] [PDF]

				T. Welbourne, E. Friday, R. Fowler, F. Turturro, and I. Nissim Troglitazone acts by PPAR{gamma} and PPAR{gamma}-independent pathways on LLC-PK1-F+ acid-base metabolism Am J Physiol Renal Physiol, January 1, 2004; 286(1): F100 - F110. [Abstract] [Full Text] [PDF]

				P. Misra, R. Chakrabarti, R. K. Vikramadithyan, G. Bolusu, S. Juluri, J. Hiriyan, C. Gershome, A. Rajjak, P. Kashireddy, S. Yu, et al. PAT5A: A Partial Agonist of Peroxisome Proliferator-Activated Receptor {gamma} Is a Potent Antidiabetic Thiazolidinedione Yet Weakly Adipogenic J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 763 - 771. [Abstract] [Full Text] [PDF]

				D. Bruemmer, F. Yin, J. Liu, J. P. Berger, T. Kiyono, J. Chen, E. Fleck, A. J. Van Herle, B. M. Forman, and R. E. Law Peroxisome Proliferator-Activated Receptor {gamma} Inhibits Expression of Minichromosome Maintenance Proteins in Vascular Smooth Muscle Cells Mol. Endocrinol., June 1, 2003; 17(6): 1005 - 1018. [Abstract] [Full Text] [PDF]

				M. Arici, R. Chana, A. Lewington, J. Brown, and N. J. Brunskill Stimulation of Proximal Tubular Cell Apoptosis by Albumin-Bound Fatty Acids Mediated by Peroxisome Proliferator Activated Receptor-{gamma} J. Am. Soc. Nephrol., January 1, 2003; 14(1): 17 - 27. [Abstract] [Full Text] [PDF]

				G. Coates, I. Nissim, H. Battarbee, and T. Welbourne Glitazones regulate glutamine metabolism by inducing a cellular acidosis in MDCK cells Am J Physiol Endocrinol Metab, October 1, 2002; 283(4): E729 - E737. [Abstract] [Full Text] [PDF]

				M. F. M. Mitwally, S. F. Witchel, and R. F. Casper Troglitazone: A Possible Modulator of Ovarian Steroidogenesis Reproductive Sciences, May 1, 2002; 9(3): 163 - 167. [Abstract] [PDF]

				Y. Li and M. A. Lazar Differential Gene Regulation by PPAR{gamma} Agonist and Constitutively Active PPAR{gamma}2 Mol. Endocrinol., May 1, 2002; 16(5): 1040 - 1048. [Abstract] [Full Text] [PDF]

				A. V. Pontsler, A. St. Hilaire, G. K. Marathe, G. A. Zimmerman, and T. M. McIntyre Cyclooxygenase-2 Is Induced in Monocytes by Peroxisome Proliferator Activated Receptor gamma and Oxidized Alkyl Phospholipids from Oxidized Low Density Lipoprotein J. Biol. Chem., April 5, 2002; 277(15): 13029 - 13036. [Abstract] [Full Text] [PDF]

				M. A. Khan, J. V. St. Peter, and J. L. Xue A Prospective, Randomized Comparison of the Metabolic Effects of Pioglitazone or Rosiglitazone in Patients With Type 2 Diabetes Who Were Previously Treated With Troglitazone Diabetes Care, April 1, 2002; 25(4): 708 - 711. [Abstract] [Full Text] [PDF]

				G. F. Davies, P. J. McFie, R. L. Khandelwal, and W. J. Roesler Unique Ability of Troglitazone to Up-Regulate Peroxisome Proliferator-Activated Receptor-gamma Expression in Hepatocytes J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 72 - 77. [Abstract] [Full Text] [PDF]

				D. J. A. Adamson, D. Frew, R. Tatoud, C. R. Wolf, and C. N. A. Palmer Diclofenac Antagonizes Peroxisome Proliferator-Activated Receptor-gamma Signaling Mol. Pharmacol., January 1, 2002; 61(1): 7 - 12. [Abstract] [Full Text] [PDF]

				R. Routh, K. McCarthy, and T. Welbourne Troglitazone inhibits glutamine metabolism in rat mesangial cells Am J Physiol Endocrinol Metab, January 1, 2002; 282(1): E231 - E238. [Abstract] [Full Text] [PDF]

				A. L. Hevener, D. Reichart, A. Janez, and J. Olefsky Thiazolidinedione Treatment Prevents Free Fatty Acid-Induced Insulin Resistance in Male Wistar Rats Diabetes, October 1, 2001; 50(10): 2316 - 2322. [Abstract] [Full Text]

				W.-H. Lin, K. C. Chiu, H.-M. Chang, K.-C. Lee, T.-Y. Tai, and L.-M. Chuang Molecular scanning of the human sorbin and SH3-domain-containing-1 (SORBS1) gene: positive association of the T228A polymorphism with obesity and type 2 diabetes Hum. Mol. Genet., August 1, 2001; 10(17): 1753 - 1760. [Abstract] [Full Text] [PDF]

				H. S. Camp, A. Chaudhry, and T. Leff A Novel Potent Antagonist of Peroxisome Proliferator-Activated Receptor {{gamma}} Blocks Adipocyte Differentiation But Does Not Revert the Phenotype of Terminally Differentiated Adipocytes Endocrinology, July 1, 2001; 142(7): 3207 - 3213. [Abstract] [Full Text] [PDF]

				M. Iwata, T. Haruta, I. Usui, Y. Takata, A. Takano, T. Uno, J. Kawahara, E. Ueno, T. Sasaoka, O. Ishibashi, et al. Pioglitazone Ameliorates Tumor Necrosis Factor-{alpha}-Induced Insulin Resistance by a Mechanism Independent of Adipogenic Activity of Peroxisome Proliferator-Activated Receptor-{gamma} Diabetes, May 1, 2001; 50(5): 1083 - 1092. [Abstract] [Full Text]

				W. Arlt, R. J. Auchus, and W. L. Miller Thiazolidinediones but Not Metformin Directly Inhibit the Steroidogenic Enzymes P450c17 and 3beta -Hydroxysteroid Dehydrogenase J. Biol. Chem., May 11, 2001; 276(20): 16767 - 16771. [Abstract] [Full Text] [PDF]